OpenURL Connection Search

Select item for more details and to access through your institution.

A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans.
Published in:
Clinical Pharmacology & Therapeutics, 2010, v. 87, n. 4, p. 445, doi. 10.1038/clpt.2009.291
By:
- Voora, D.;
- Koboldt, D. C.;
- King, C. R.;
- Lenzini, P. A.;
- Eby, C. S.;
- Porche-Sorbet, R.;
- Deych, E.;
- Crankshaw, M.;
- Milligan, P. E.;
- McLeod, H. L.;
- Patel, S. R.;
- Cavallari, L. H.;
- Ridker, P. M.;
- Grice, G. R.;
- Miller, R. D.;
- Gage, B. F.
Publication type:
Article
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin.
Published in:
Clinical Pharmacology & Therapeutics, 2008, v. 84, n. 3, p. 326, doi. 10.1038/clpt.2008.10
By:
- Gage, B. F.;
- Eby, C.;
- Johnson, J. A.;
- Deych, E.;
- Rieder, M. J.;
- Ridker, P. M.;
- Milligan, P. E.;
- Grice, G.;
- Lenzini, P.;
- Rettie, A. E.;
- Aquilante, C. L.;
- Grosso, L.;
- Marsh, S.;
- Langaee, T.;
- Farnett, L. E.;
- Voora, D.;
- Veenstra, D. L.;
- Glynn, R. J.;
- Barrett, A.;
- McLeod, H. L.
Publication type:
Article
Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study.
Published in:
Lupus, 2019, v. 28, n. 14, p. 1640, doi. 10.1177/0961203319886069
By:
- Eudy, A M;
- Voora, D;
- Myers, R A;
- Clowse, M E B
Publication type:
Article
Phenotype Standardization for Statin-Induced Myotoxicity.
Published in:
Clinical Pharmacology & Therapeutics, 2014, v. 96, n. 4, p. 470, doi. 10.1038/clpt.2014.121
By:
- Alfirevic, A;
- Neely, D;
- Armitage, J;
- Chinoy, H;
- Cooper, R G;
- Laaksonen, R;
- Carr, D F;
- Bloch, K M;
- Fahy, J;
- Hanson, A;
- Yue, Q‐Y;
- Wadelius, M;
- Maitland‐van Der Zee, A H;
- Voora, D;
- Psaty, B M;
- Palmer, C N A;
- Pirmohamed, M
Publication type:
Article
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update.
Published in:
Clinical Pharmacology & Therapeutics, 2014, v. 96, n. 4, p. 423, doi. 10.1038/clpt.2014.125
By:
- Ramsey, L B;
- Johnson, S G;
- Caudle, K E;
- Haidar, C E;
- Voora, D;
- Wilke, R A;
- Maxwell, W D;
- McLeod, H L;
- Krauss, R M;
- Roden, D M;
- Feng, Q;
- Cooper‐DeHoff, R M;
- Gong, L;
- Klein, T E;
- Wadelius, M;
- Niemi, M
Publication type:
Article
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy.
Published in:
Clinical Pharmacology & Therapeutics, 2012, v. 92, n. 1, p. 112, doi. 10.1038/clpt.2012.57
By:
- Wilke, R A;
- Ramsey, L B;
- Johnson, S G;
- Maxwell, W D;
- McLeod, H L;
- Voora, D;
- Krauss, R M;
- Roden, D M;
- Feng, Q;
- Cooper-DeHoff, R M;
- Gong, L;
- Klein, T E;
- Wadelius, M;
- Niemi, M
Publication type:
Article

Found: 6

A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans.

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin.

Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study.

Phenotype Standardization for Statin-Induced Myotoxicity.

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update.

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy.